Latest News in the pharma Industry
Research & Development
Sanofi, DNDi seek EMA review for sleeping sickness treatment
1 Feb 2018
Fexinidazole would be first all-oral treatment under investigation for both first and second stages of sleeping sickness, a fatal disease, endemic in Africa.
Read more.jpg)
Collaboration expanded to explore synthetically feasible chemical space
25 Jan 2018
Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.
Read more
Partnership in AI and machine learning for target discovery
23 Jan 2018
LifeArc and Milner Therapeutics Institute to develop, validate and integrate cutting-edge machine learning approaches into drug discovery processes.
Read more
Charles River acquisition enhances discovery expertise
18 Jan 2018
KWS increases Charles River's ability to support clients’ early-stage drug research in critical therapeutic areas.
Read more
2017: A year of innovation and advances
14 Jan 2018
A summary and highlights of new drug therapy approvals and other drug therapy advances in 2017 by FDA's CDER.
Read more
New automated VPT systems for topical drug performance testing
11 Jan 2018
The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.
Read more
3D human sebaceous glands technology for skin care applications
9 Jan 2018
New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.
Read more.png)
Sangamo and Pfizer collaborate to develop zinc finger protein gene therapy for ALS
7 Jan 2018
"The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation."
Read more.png)
Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia
4 Jan 2018
Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%.
Read more
Momenta and Mylan to development proposed biosimilar to Eylea
4 Jan 2018
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018.
Read more.png)
Novartis Kisqali receives FDA Breakthrough Therapy designation
3 Jan 2018
Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal women who received no prior endocrine therapy for adva...
Read more.png)
Scholar Rock announces $47 million Series C financing to advance innovative pipeline
3 Jan 2018
SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow.
Read more